JP2013533228A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533228A5
JP2013533228A5 JP2013513651A JP2013513651A JP2013533228A5 JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5 JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
solvate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013513651A
Other languages
English (en)
Japanese (ja)
Other versions
JP5791707B2 (ja
JP2013533228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/059300 external-priority patent/WO2011154359A1/de
Publication of JP2013533228A publication Critical patent/JP2013533228A/ja
Publication of JP2013533228A5 publication Critical patent/JP2013533228A5/ja
Application granted granted Critical
Publication of JP5791707B2 publication Critical patent/JP5791707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013513651A 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用 Active JP5791707B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10165550.4 2010-06-10
EP10165550 2010-06-10
EP11158464 2011-03-16
EP11158464.5 2011-03-16
PCT/EP2011/059300 WO2011154359A1 (de) 2010-06-10 2011-06-06 Neue auristatin-derivate und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013533228A JP2013533228A (ja) 2013-08-22
JP2013533228A5 true JP2013533228A5 (enExample) 2014-07-03
JP5791707B2 JP5791707B2 (ja) 2015-10-07

Family

ID=44275637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513651A Active JP5791707B2 (ja) 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用

Country Status (7)

Country Link
US (1) US8722629B2 (enExample)
EP (1) EP2579887B1 (enExample)
JP (1) JP5791707B2 (enExample)
CN (1) CN103200950B (enExample)
CA (1) CA2801971C (enExample)
ES (1) ES2528956T3 (enExample)
WO (1) WO2011154359A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
CA2829736C (en) 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatins and use thereof
EP3501546A3 (de) * 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SG11201605260VA (en) 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
EP3134124B1 (en) 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
CN106470708B (zh) 2014-04-25 2019-12-31 皮埃尔法布雷医药公司 抗体-药物-缀合物和其用于治疗癌症的用途
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN108690119B (zh) * 2018-06-04 2022-04-19 莎穆(上海)生物科技有限公司 一种伊文思蓝修饰的多肽类前药及其制备和应用
EP4319820A1 (en) 2021-04-10 2024-02-14 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー/エス 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Slitrk6結合劑、其共軛物及使用彼之方法
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2315230C (en) 1998-01-09 2004-06-29 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
EP1537140B1 (en) * 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP3501546A3 (de) * 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung

Similar Documents

Publication Publication Date Title
US11857522B2 (en) Compositions containing tucaresol or its analogs
JP2013540114A5 (enExample)
JP2020506951A5 (enExample)
JP2014515735A5 (enExample)
KR20180084063A (ko) 아르기닌 활성 억제용 조성물 및 방법
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2010539110A5 (enExample)
JP2009536620A5 (enExample)
JP2011509309A5 (enExample)
JP2020523388A5 (enExample)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
EP3890749A1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2021096811A1 (en) Tucaresol derivatives and uses thereof
JP2019535723A5 (enExample)
JP2013522368A5 (enExample)
JPWO2023195529A5 (enExample)
KR102904026B1 (ko) 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
JP2017525717A5 (enExample)
RU2001135802A (ru) Антагонисты рецептора брадикинина
JP2011518168A5 (enExample)
JP2010514734A5 (enExample)
RU2015113959A (ru) Индолины
JP2017535566A5 (enExample)
JP2015524835A5 (enExample)
RU2005138143A (ru) Митилиндолы и метилпирролопиридины в качестве l-1-адренергических агонистов